EcoDrugPlus

Emap Like 4

Ensembl ID : ENSLBEG00000022841
Gene Symbol: EML4
4 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSLBEG00000027561
Gene Symbol: EPHA3
3 Cross references
209 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSLBEG00000024223
Gene Symbol: F2RL3
4 Cross references
195 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSLBEG00000011605
Gene Symbol: FYN
4 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSLBEG00000004573
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

G-Protein Coupled Receptor 84-Like

Ensembl ID : ENSLBEG00000019651
Gene Symbol: LOC109993781
3 Cross references
113 Possible Orthologues:

G1/s-Specific Cyclin-D1-Like

Ensembl ID : ENSLBEG00000021817
Gene Symbol: LOC110005338
2 Cross references
206 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSLBEG00000027353
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSLBEG00000013777
Gene Symbol: ITK
3 Cross references
205 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSLBEG00000006464
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSLBEG00000025804
Gene Symbol: JAK2B
1 Cross references
191 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSLBEG00000028450
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).